Laura Saba
Concepts (705)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carotid Stenosis | 8 | 2020 | 107 | 3.300 |
Why?
| | Plaque, Atherosclerotic | 4 | 2020 | 61 | 2.230 |
Why?
| | Alcohol Drinking | 18 | 2021 | 858 | 1.770 |
Why?
| | Quantitative Trait Loci | 25 | 2025 | 389 | 1.710 |
Why?
| | Carotid Arteries | 5 | 2020 | 208 | 1.520 |
Why?
| | Adrenocortical Carcinoma | 8 | 2026 | 72 | 1.320 |
Why?
| | Transcriptome | 10 | 2025 | 1059 | 1.320 |
Why?
| | Ethanol | 16 | 2024 | 634 | 1.290 |
Why?
| | Brain | 23 | 2026 | 3009 | 1.250 |
Why?
| | Adrenal Cortex Neoplasms | 7 | 2026 | 70 | 1.200 |
Why?
| | Gene Regulatory Networks | 7 | 2023 | 318 | 1.170 |
Why?
| | High-Throughput Nucleotide Sequencing | 7 | 2024 | 539 | 1.040 |
Why?
| | Magnetic Resonance Imaging, Cine | 2 | 2025 | 214 | 1.000 |
Why?
| | Quantitative Trait, Heritable | 7 | 2017 | 116 | 0.980 |
Why?
| | Gene Expression Profiling | 16 | 2021 | 1794 | 0.950 |
Why?
| | Rats, Inbred Strains | 7 | 2019 | 323 | 0.880 |
Why?
| | Magnetic Resonance Imaging | 7 | 2025 | 3980 | 0.880 |
Why?
| | Mitotane | 6 | 2025 | 10 | 0.840 |
Why?
| | Systems Biology | 3 | 2021 | 68 | 0.830 |
Why?
| | Myocarditis | 1 | 2025 | 102 | 0.820 |
Why?
| | Rats | 24 | 2026 | 5613 | 0.810 |
Why?
| | Trace Elements | 2 | 2021 | 52 | 0.800 |
Why?
| | Takotsubo Cardiomyopathy | 1 | 2023 | 3 | 0.790 |
Why?
| | Hemorrhage | 2 | 2019 | 832 | 0.760 |
Why?
| | Genetic Predisposition to Disease | 13 | 2024 | 2458 | 0.740 |
Why?
| | Liver | 10 | 2024 | 1916 | 0.740 |
Why?
| | Cerebrovascular Disorders | 2 | 2022 | 106 | 0.730 |
Why?
| | MicroRNAs | 6 | 2019 | 694 | 0.690 |
Why?
| | Atrial Appendage | 1 | 2022 | 36 | 0.680 |
Why?
| | Phenotype | 16 | 2026 | 3216 | 0.670 |
Why?
| | Sequence Analysis, RNA | 7 | 2022 | 443 | 0.670 |
Why?
| | Polymorphism, Single Nucleotide | 18 | 2025 | 2223 | 0.660 |
Why?
| | Animals | 65 | 2026 | 38410 | 0.660 |
Why?
| | Precision Medicine | 1 | 2025 | 464 | 0.650 |
Why?
| | Polyadenylation | 1 | 2021 | 39 | 0.640 |
Why?
| | RNA | 6 | 2021 | 916 | 0.640 |
Why?
| | Protein Carbonylation | 7 | 2019 | 57 | 0.630 |
Why?
| | RNA, Long Noncoding | 2 | 2020 | 173 | 0.630 |
Why?
| | Liver Diseases, Alcoholic | 5 | 2024 | 98 | 0.610 |
Why?
| | Atherosclerosis | 2 | 2021 | 411 | 0.600 |
Why?
| | Mustard Gas | 3 | 2025 | 77 | 0.600 |
Why?
| | Chemical Warfare Agents | 3 | 2025 | 89 | 0.590 |
Why?
| | Alcoholism | 9 | 2026 | 838 | 0.590 |
Why?
| | Adipose Tissue | 2 | 2020 | 646 | 0.570 |
Why?
| | Software | 8 | 2025 | 683 | 0.570 |
Why?
| | Drug Tolerance | 4 | 2020 | 99 | 0.560 |
Why?
| | Cerebral Hemorrhage | 1 | 2019 | 125 | 0.560 |
Why?
| | Male | 80 | 2026 | 73950 | 0.540 |
Why?
| | Tunica Media | 1 | 2018 | 38 | 0.540 |
Why?
| | Tunica Intima | 1 | 2018 | 79 | 0.530 |
Why?
| | Genetic Variation | 5 | 2024 | 995 | 0.520 |
Why?
| | Databases, Genetic | 5 | 2017 | 240 | 0.520 |
Why?
| | Antineoplastic Agents, Hormonal | 5 | 2025 | 196 | 0.520 |
Why?
| | Complement C3 | 5 | 2024 | 188 | 0.500 |
Why?
| | Alcohol-Related Disorders | 1 | 2018 | 126 | 0.500 |
Why?
| | Humans | 103 | 2026 | 147293 | 0.490 |
Why?
| | Genome-Wide Association Study | 4 | 2026 | 1496 | 0.490 |
Why?
| | Dexamethasone | 4 | 2025 | 368 | 0.480 |
Why?
| | Tomography, X-Ray Computed | 8 | 2021 | 2791 | 0.480 |
Why?
| | Middle Aged | 46 | 2025 | 36821 | 0.480 |
Why?
| | Female | 75 | 2026 | 80076 | 0.460 |
Why?
| | Genomics | 6 | 2024 | 839 | 0.460 |
Why?
| | beta-Thalassemia | 5 | 2025 | 40 | 0.460 |
Why?
| | Brain Ischemia | 1 | 2019 | 362 | 0.450 |
Why?
| | Central Nervous System Depressants | 4 | 2010 | 84 | 0.440 |
Why?
| | Aged | 30 | 2024 | 26514 | 0.430 |
Why?
| | Endoplasmic Reticulum Stress | 2 | 2026 | 121 | 0.420 |
Why?
| | Angiography | 4 | 2010 | 209 | 0.420 |
Why?
| | Retrospective Studies | 19 | 2025 | 17560 | 0.410 |
Why?
| | Computed Tomography Angiography | 3 | 2021 | 153 | 0.410 |
Why?
| | Corneal Injuries | 2 | 2025 | 42 | 0.410 |
Why?
| | Models, Statistical | 1 | 2018 | 677 | 0.410 |
Why?
| | Aged, 80 and over | 13 | 2024 | 8430 | 0.390 |
Why?
| | Internet | 6 | 2010 | 696 | 0.380 |
Why?
| | Oligonucleotide Array Sequence Analysis | 6 | 2019 | 751 | 0.380 |
Why?
| | Complement Activation | 4 | 2025 | 401 | 0.370 |
Why?
| | Mice | 34 | 2025 | 18491 | 0.370 |
Why?
| | Bayes Theorem | 5 | 2020 | 428 | 0.370 |
Why?
| | Severity of Illness Index | 5 | 2021 | 2973 | 0.350 |
Why?
| | Complement Inactivating Agents | 2 | 2025 | 76 | 0.350 |
Why?
| | Genome | 4 | 2024 | 306 | 0.340 |
Why?
| | Adult | 43 | 2025 | 41405 | 0.330 |
Why?
| | Oxidative Stress | 7 | 2026 | 1368 | 0.330 |
Why?
| | Aldehydes | 5 | 2019 | 140 | 0.320 |
Why?
| | Ultrasonography | 3 | 2020 | 795 | 0.320 |
Why?
| | Heart Ventricles | 2 | 2026 | 767 | 0.320 |
Why?
| | Glutathione Transferase | 4 | 2019 | 92 | 0.320 |
Why?
| | Mice, Inbred Strains | 9 | 2020 | 397 | 0.310 |
Why?
| | Health Education | 3 | 2008 | 346 | 0.300 |
Why?
| | ROC Curve | 4 | 2019 | 626 | 0.290 |
Why?
| | Endometriosis | 2 | 2020 | 58 | 0.290 |
Why?
| | Rats, Wistar | 3 | 2020 | 450 | 0.290 |
Why?
| | Carotid Artery Diseases | 1 | 2009 | 70 | 0.290 |
Why?
| | Genetic Association Studies | 5 | 2017 | 374 | 0.280 |
Why?
| | Oxycodone | 2 | 2026 | 52 | 0.280 |
Why?
| | Synaptic Transmission | 1 | 2010 | 293 | 0.280 |
Why?
| | Tomography, Spiral Computed | 1 | 2008 | 30 | 0.280 |
Why?
| | Models, Genetic | 6 | 2025 | 536 | 0.270 |
Why?
| | Apoptosis | 4 | 2026 | 2454 | 0.270 |
Why?
| | Brain Diseases | 1 | 2009 | 158 | 0.260 |
Why?
| | Nanoparticles | 4 | 2025 | 524 | 0.260 |
Why?
| | Gastrointestinal Microbiome | 2 | 2026 | 773 | 0.250 |
Why?
| | Cornea | 2 | 2025 | 156 | 0.250 |
Why?
| | Genotype | 11 | 2025 | 1875 | 0.250 |
Why?
| | Tandem Mass Spectrometry | 5 | 2024 | 575 | 0.250 |
Why?
| | Propidium | 1 | 2026 | 8 | 0.250 |
Why?
| | Point Mutation | 2 | 2001 | 245 | 0.240 |
Why?
| | Annexin A5 | 1 | 2026 | 23 | 0.240 |
Why?
| | Polyploidy | 1 | 2026 | 14 | 0.240 |
Why?
| | Contrast Media | 5 | 2021 | 500 | 0.240 |
Why?
| | Genes, Regulator | 1 | 2006 | 35 | 0.240 |
Why?
| | Genetic Background | 1 | 2026 | 16 | 0.240 |
Why?
| | Receptors, GABA-A | 3 | 2026 | 138 | 0.240 |
Why?
| | Breast Neoplasms | 6 | 2023 | 2420 | 0.230 |
Why?
| | Triterpenes | 1 | 2026 | 27 | 0.230 |
Why?
| | PTEN Phosphohydrolase | 2 | 2018 | 165 | 0.230 |
Why?
| | Adenylyl Cyclases | 3 | 2012 | 60 | 0.230 |
Why?
| | Gene Expression Regulation | 8 | 2025 | 2625 | 0.230 |
Why?
| | Smoking Prevention | 1 | 2006 | 167 | 0.230 |
Why?
| | Necrosis | 1 | 2026 | 245 | 0.220 |
Why?
| | Microfilament Proteins | 1 | 2026 | 135 | 0.220 |
Why?
| | Activating Transcription Factor 3 | 1 | 2025 | 4 | 0.220 |
Why?
| | Rats, Inbred SHR | 4 | 2018 | 36 | 0.220 |
Why?
| | Activating Transcription Factor 4 | 1 | 2025 | 22 | 0.220 |
Why?
| | Limbus Corneae | 1 | 2025 | 8 | 0.220 |
Why?
| | Iron | 2 | 2021 | 361 | 0.220 |
Why?
| | Phytochemicals | 1 | 2025 | 13 | 0.220 |
Why?
| | Recombination, Genetic | 2 | 2017 | 205 | 0.220 |
Why?
| | Tea | 1 | 2025 | 17 | 0.220 |
Why?
| | Nanomedicine | 1 | 2025 | 47 | 0.220 |
Why?
| | Hypothalamo-Hypophyseal System | 4 | 2017 | 201 | 0.210 |
Why?
| | Signal Transduction | 10 | 2026 | 5272 | 0.210 |
Why?
| | Polyethylene Glycols | 3 | 2025 | 649 | 0.210 |
Why?
| | Pituitary-Adrenal System | 3 | 2017 | 166 | 0.210 |
Why?
| | Mice, Inbred C57BL | 12 | 2025 | 6041 | 0.210 |
Why?
| | Heart Transplantation | 2 | 2021 | 682 | 0.200 |
Why?
| | Endarterectomy, Carotid | 2 | 2017 | 64 | 0.200 |
Why?
| | Doxorubicin | 3 | 2025 | 411 | 0.200 |
Why?
| | Magnesium | 2 | 2021 | 157 | 0.200 |
Why?
| | Algorithms | 4 | 2023 | 1868 | 0.200 |
Why?
| | Stents | 1 | 2008 | 570 | 0.200 |
Why?
| | Analgesics, Opioid | 3 | 2026 | 1167 | 0.200 |
Why?
| | Base Sequence | 6 | 2021 | 2175 | 0.190 |
Why?
| | Gastrointestinal Tract | 1 | 2026 | 204 | 0.190 |
Why?
| | Cysteine | 1 | 2024 | 211 | 0.190 |
Why?
| | Diastole | 1 | 2023 | 147 | 0.190 |
Why?
| | Analgesia | 1 | 2024 | 106 | 0.190 |
Why?
| | Germ-Line Mutation | 1 | 2024 | 180 | 0.190 |
Why?
| | Immunoglobulins | 2 | 2024 | 163 | 0.190 |
Why?
| | Sensitivity and Specificity | 4 | 2019 | 2017 | 0.190 |
Why?
| | Rats, Inbred BN | 3 | 2018 | 56 | 0.180 |
Why?
| | Lysine | 1 | 2024 | 305 | 0.180 |
Why?
| | Dextrans | 2 | 2024 | 84 | 0.180 |
Why?
| | Acute Disease | 1 | 2025 | 1049 | 0.180 |
Why?
| | Whole Genome Sequencing | 2 | 2024 | 183 | 0.180 |
Why?
| | Phosphorus | 2 | 2021 | 90 | 0.180 |
Why?
| | Immunoconjugates | 1 | 2023 | 138 | 0.180 |
Why?
| | Fetal Development | 2 | 2022 | 298 | 0.180 |
Why?
| | Behavior, Addictive | 2 | 2020 | 89 | 0.170 |
Why?
| | Leukopenia | 1 | 2021 | 33 | 0.170 |
Why?
| | Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 21 | 0.170 |
Why?
| | Multifactorial Inheritance | 2 | 2025 | 231 | 0.170 |
Why?
| | Myocytes, Cardiac | 1 | 2026 | 547 | 0.170 |
Why?
| | Proteome | 3 | 2024 | 520 | 0.170 |
Why?
| | Heart Atria | 1 | 2022 | 141 | 0.170 |
Why?
| | Anti-Inflammatory Agents | 1 | 2025 | 481 | 0.170 |
Why?
| | Magnesium Deficiency | 1 | 2020 | 2 | 0.170 |
Why?
| | Chromatography, Liquid | 5 | 2024 | 453 | 0.170 |
Why?
| | Selenium | 1 | 2021 | 50 | 0.160 |
Why?
| | Myocardium | 2 | 2018 | 947 | 0.160 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2021 | 141 | 0.160 |
Why?
| | Mycophenolic Acid | 1 | 2021 | 119 | 0.160 |
Why?
| | Matrix Metalloproteinases | 1 | 2021 | 95 | 0.160 |
Why?
| | Protein Processing, Post-Translational | 3 | 2024 | 480 | 0.160 |
Why?
| | Hydroxycholesterols | 1 | 2020 | 5 | 0.160 |
Why?
| | Copper | 1 | 2021 | 122 | 0.160 |
Why?
| | Stem Cells | 1 | 2025 | 630 | 0.160 |
Why?
| | alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 1 | 2020 | 15 | 0.160 |
Why?
| | Echocardiography | 1 | 2023 | 652 | 0.150 |
Why?
| | Iron Overload | 2 | 2025 | 19 | 0.150 |
Why?
| | Sigmoid Diseases | 1 | 2020 | 14 | 0.150 |
Why?
| | Rectal Diseases | 1 | 2020 | 24 | 0.150 |
Why?
| | Complement System Proteins | 2 | 2024 | 320 | 0.150 |
Why?
| | Nicotinamide Mononucleotide | 1 | 2019 | 9 | 0.150 |
Why?
| | Hydrocarbons, Chlorinated | 1 | 2019 | 21 | 0.150 |
Why?
| | Osteoprotegerin | 3 | 2009 | 24 | 0.150 |
Why?
| | Risk | 2 | 2021 | 927 | 0.150 |
Why?
| | Epithelium, Corneal | 1 | 2019 | 41 | 0.150 |
Why?
| | User-Computer Interface | 1 | 2020 | 165 | 0.150 |
Why?
| | Rabbits | 3 | 2025 | 654 | 0.150 |
Why?
| | Genetic Markers | 1 | 2020 | 338 | 0.150 |
Why?
| | Pancreatic Diseases | 1 | 2020 | 66 | 0.150 |
Why?
| | Pesticides | 1 | 2019 | 59 | 0.150 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2022 | 627 | 0.150 |
Why?
| | Anthracenes | 1 | 2019 | 31 | 0.150 |
Why?
| | Gene Expression | 3 | 2014 | 1481 | 0.150 |
Why?
| | Reflex, Righting | 2 | 2018 | 15 | 0.140 |
Why?
| | Drosophila | 1 | 2020 | 168 | 0.140 |
Why?
| | Mice, Inbred DBA | 5 | 2019 | 182 | 0.140 |
Why?
| | Opsonin Proteins | 1 | 2019 | 19 | 0.140 |
Why?
| | Protein Corona | 1 | 2019 | 9 | 0.140 |
Why?
| | Acylation | 1 | 2019 | 30 | 0.140 |
Why?
| | Cushing Syndrome | 2 | 2010 | 10 | 0.140 |
Why?
| | Fluorenes | 1 | 2019 | 45 | 0.140 |
Why?
| | Eicosanoids | 1 | 2019 | 58 | 0.140 |
Why?
| | Chimera | 1 | 2019 | 62 | 0.140 |
Why?
| | Pharmaceutical Preparations | 1 | 2020 | 172 | 0.140 |
Why?
| | Liposomes | 2 | 2019 | 268 | 0.140 |
Why?
| | Biomarkers | 7 | 2020 | 4351 | 0.140 |
Why?
| | Learning Curve | 1 | 2019 | 71 | 0.140 |
Why?
| | Antioxidants | 2 | 2019 | 550 | 0.140 |
Why?
| | Drosophila Proteins | 1 | 2020 | 215 | 0.140 |
Why?
| | Steroid 11-beta-Hydroxylase | 1 | 2018 | 2 | 0.140 |
Why?
| | Antineoplastic Agents | 2 | 2026 | 2231 | 0.140 |
Why?
| | Reproducibility of Results | 3 | 2022 | 3448 | 0.140 |
Why?
| | Lymphocytes | 1 | 2020 | 378 | 0.140 |
Why?
| | Pulmonary Embolism | 1 | 2021 | 246 | 0.140 |
Why?
| | Metabolic Clearance Rate | 1 | 2018 | 115 | 0.140 |
Why?
| | Unsupervised Machine Learning | 1 | 2018 | 23 | 0.140 |
Why?
| | Cell Degranulation | 1 | 2018 | 40 | 0.140 |
Why?
| | Proton Pump Inhibitors | 1 | 2019 | 109 | 0.140 |
Why?
| | Alveolar Epithelial Cells | 1 | 2019 | 121 | 0.130 |
Why?
| | Sex Characteristics | 4 | 2021 | 799 | 0.130 |
Why?
| | Hallucinogens | 1 | 2020 | 112 | 0.130 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2021 | 277 | 0.130 |
Why?
| | Zinc | 1 | 2021 | 309 | 0.130 |
Why?
| | Angiography, Digital Subtraction | 1 | 2018 | 51 | 0.130 |
Why?
| | Silver | 1 | 2018 | 36 | 0.130 |
Why?
| | Smoking | 2 | 2020 | 1483 | 0.130 |
Why?
| | Gene Knockout Techniques | 1 | 2018 | 122 | 0.130 |
Why?
| | Hippocampus | 2 | 2022 | 989 | 0.130 |
Why?
| | Receptors, Nicotinic | 1 | 2020 | 328 | 0.130 |
Why?
| | Food Preferences | 2 | 2009 | 126 | 0.130 |
Why?
| | Ferrosoferric Oxide | 1 | 2017 | 25 | 0.130 |
Why?
| | Graft Rejection | 1 | 2021 | 523 | 0.130 |
Why?
| | Lung | 2 | 2021 | 4141 | 0.130 |
Why?
| | Hepatitis | 1 | 2017 | 43 | 0.130 |
Why?
| | Monocytes | 1 | 2020 | 539 | 0.130 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2018 | 103 | 0.130 |
Why?
| | Feasibility Studies | 1 | 2022 | 1147 | 0.130 |
Why?
| | Computational Biology | 3 | 2017 | 677 | 0.130 |
Why?
| | Adipose Tissue, Brown | 1 | 2017 | 60 | 0.130 |
Why?
| | Interleukin-6 | 3 | 2006 | 784 | 0.130 |
Why?
| | Pancreas | 1 | 2020 | 345 | 0.130 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2020 | 273 | 0.130 |
Why?
| | Web Browser | 1 | 2017 | 12 | 0.130 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2025 | 1457 | 0.130 |
Why?
| | Disease Models, Animal | 7 | 2025 | 4604 | 0.130 |
Why?
| | Risk Factors | 6 | 2019 | 11017 | 0.120 |
Why?
| | Models, Animal | 1 | 2019 | 394 | 0.120 |
Why?
| | Gynecology | 1 | 2019 | 184 | 0.120 |
Why?
| | Lung Diseases, Interstitial | 1 | 2023 | 675 | 0.120 |
Why?
| | Globins | 2 | 1997 | 21 | 0.120 |
Why?
| | Cholestasis | 1 | 2019 | 217 | 0.120 |
Why?
| | Lod Score | 1 | 2016 | 62 | 0.120 |
Why?
| | Mast Cells | 1 | 2018 | 148 | 0.120 |
Why?
| | Gene Ontology | 1 | 2016 | 55 | 0.120 |
Why?
| | Pain Threshold | 2 | 2010 | 72 | 0.120 |
Why?
| | Chromosomes, Mammalian | 1 | 2016 | 29 | 0.120 |
Why?
| | Chemical and Drug Induced Liver Injury, Chronic | 1 | 2016 | 11 | 0.120 |
Why?
| | Fatty Liver, Alcoholic | 1 | 2016 | 14 | 0.120 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2016 | 21 | 0.120 |
Why?
| | End Stage Liver Disease | 1 | 2017 | 95 | 0.120 |
Why?
| | Calcium | 2 | 2021 | 1197 | 0.120 |
Why?
| | Liver Diseases | 1 | 2019 | 307 | 0.120 |
Why?
| | Choice Behavior | 2 | 2014 | 181 | 0.120 |
Why?
| | Cell Line, Tumor | 5 | 2026 | 3565 | 0.120 |
Why?
| | Liver Cirrhosis, Alcoholic | 1 | 2015 | 19 | 0.120 |
Why?
| | von Willebrand Factor | 1 | 2016 | 85 | 0.110 |
Why?
| | Hypnotics and Sedatives | 1 | 2018 | 226 | 0.110 |
Why?
| | Linkage Disequilibrium | 1 | 2016 | 259 | 0.110 |
Why?
| | Mitochondria | 2 | 2021 | 1000 | 0.110 |
Why?
| | Consensus | 1 | 2018 | 476 | 0.110 |
Why?
| | beta Karyopherins | 1 | 2015 | 9 | 0.110 |
Why?
| | Hydrocortisone | 4 | 2012 | 300 | 0.110 |
Why?
| | Opioid-Related Disorders | 1 | 2024 | 617 | 0.110 |
Why?
| | Seizures | 1 | 2020 | 491 | 0.110 |
Why?
| | Databases, Nucleic Acid | 1 | 2015 | 39 | 0.110 |
Why?
| | Receptor, Serotonin, 5-HT1A | 1 | 2015 | 37 | 0.110 |
Why?
| | Antiviral Agents | 1 | 2021 | 776 | 0.110 |
Why?
| | Herpesvirus 1, Human | 1 | 2016 | 87 | 0.110 |
Why?
| | Immune System | 1 | 2016 | 181 | 0.110 |
Why?
| | Anxiety | 1 | 2022 | 1149 | 0.110 |
Why?
| | Darkness | 1 | 2015 | 26 | 0.110 |
Why?
| | Allergens | 1 | 2018 | 391 | 0.110 |
Why?
| | Pulmonary Artery | 1 | 2021 | 1132 | 0.110 |
Why?
| | Neoplasm Proteins | 1 | 2018 | 445 | 0.110 |
Why?
| | Diet | 3 | 2008 | 1284 | 0.110 |
Why?
| | Circadian Rhythm | 2 | 2020 | 514 | 0.110 |
Why?
| | Peptides | 1 | 2020 | 1003 | 0.110 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2017 | 266 | 0.100 |
Why?
| | Neutrophils | 1 | 2020 | 1135 | 0.100 |
Why?
| | Down Syndrome | 1 | 2021 | 526 | 0.100 |
Why?
| | Species Specificity | 4 | 2014 | 547 | 0.100 |
Why?
| | Mammography | 2 | 2006 | 172 | 0.100 |
Why?
| | Cell Proliferation | 2 | 2018 | 2529 | 0.100 |
Why?
| | LDL-Receptor Related Proteins | 1 | 2013 | 6 | 0.100 |
Why?
| | Chloride Channels | 1 | 1993 | 33 | 0.100 |
Why?
| | Oxidation-Reduction | 3 | 2024 | 1077 | 0.100 |
Why?
| | ErbB Receptors | 1 | 2017 | 638 | 0.100 |
Why?
| | Proteomics | 4 | 2024 | 1203 | 0.100 |
Why?
| | Mitochondrial Proteins | 1 | 2015 | 264 | 0.100 |
Why?
| | Early Detection of Cancer | 2 | 2023 | 506 | 0.100 |
Why?
| | Glucocorticoids | 2 | 2009 | 537 | 0.100 |
Why?
| | Chromosome Mapping | 4 | 2020 | 512 | 0.100 |
Why?
| | Genes | 1 | 1993 | 230 | 0.100 |
Why?
| | Epithelial Cells | 1 | 2019 | 1141 | 0.100 |
Why?
| | Database Management Systems | 2 | 2017 | 51 | 0.100 |
Why?
| | Blood Pressure | 1 | 2020 | 1785 | 0.090 |
Why?
| | Stroke | 1 | 2022 | 1287 | 0.090 |
Why?
| | Cannabis | 1 | 2020 | 518 | 0.090 |
Why?
| | Anti-HIV Agents | 1 | 2020 | 919 | 0.090 |
Why?
| | Cross-Sectional Studies | 6 | 2025 | 6011 | 0.090 |
Why?
| | Mice, Knockout | 5 | 2019 | 3153 | 0.090 |
Why?
| | Catalase | 2 | 2017 | 134 | 0.090 |
Why?
| | Exercise | 3 | 2014 | 2219 | 0.090 |
Why?
| | Imaging, Three-Dimensional | 2 | 2015 | 587 | 0.090 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 1166 | 0.090 |
Why?
| | Feces | 2 | 2026 | 500 | 0.090 |
Why?
| | DNA Mutational Analysis | 4 | 2001 | 414 | 0.090 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2012 | 92 | 0.090 |
Why?
| | Dogs | 2 | 2025 | 518 | 0.090 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2012 | 41 | 0.090 |
Why?
| | Monoamine Oxidase | 1 | 2011 | 27 | 0.090 |
Why?
| | Transcription, Genetic | 1 | 2018 | 1456 | 0.090 |
Why?
| | Follow-Up Studies | 4 | 2021 | 5476 | 0.090 |
Why?
| | Metabolomics | 3 | 2025 | 736 | 0.080 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2015 | 379 | 0.080 |
Why?
| | Hypertension | 1 | 2020 | 1280 | 0.080 |
Why?
| | Kidney | 1 | 2019 | 1511 | 0.080 |
Why?
| | GTP-Binding Protein beta Subunits | 1 | 2010 | 17 | 0.080 |
Why?
| | Receptors, GABA | 1 | 2010 | 13 | 0.080 |
Why?
| | Rats, Long-Evans | 2 | 2021 | 128 | 0.080 |
Why?
| | Area Under Curve | 3 | 2019 | 334 | 0.080 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2015 | 434 | 0.080 |
Why?
| | Pituitary-Adrenal Function Tests | 1 | 2010 | 3 | 0.080 |
Why?
| | Bone Density | 2 | 2012 | 493 | 0.080 |
Why?
| | Inflammation | 4 | 2025 | 2920 | 0.080 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2012 | 297 | 0.080 |
Why?
| | Mice, Inbred BALB C | 3 | 2021 | 1266 | 0.080 |
Why?
| | Camptothecin | 2 | 2023 | 138 | 0.080 |
Why?
| | Colonic Diseases, Functional | 2 | 2000 | 3 | 0.080 |
Why?
| | RNA, Messenger | 5 | 2018 | 2812 | 0.080 |
Why?
| | Adaptation, Physiological | 1 | 2014 | 567 | 0.080 |
Why?
| | Adenocarcinoma | 1 | 2017 | 928 | 0.070 |
Why?
| | Postmenopause | 1 | 2012 | 394 | 0.070 |
Why?
| | Italy | 4 | 2019 | 118 | 0.070 |
Why?
| | Receptors, Mineralocorticoid | 1 | 2009 | 11 | 0.070 |
Why?
| | Morphine | 1 | 2010 | 169 | 0.070 |
Why?
| | Logistic Models | 3 | 2010 | 2142 | 0.070 |
Why?
| | Molecular Sequence Data | 6 | 2015 | 2886 | 0.070 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 2001 | 0.070 |
Why?
| | United States | 4 | 2022 | 16313 | 0.070 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2010 | 195 | 0.070 |
Why?
| | Inflammation Mediators | 2 | 2024 | 507 | 0.070 |
Why?
| | Neoplasms | 2 | 2022 | 2946 | 0.070 |
Why?
| | NF-kappa B | 2 | 2025 | 676 | 0.070 |
Why?
| | Cyclooxygenase 2 | 2 | 2019 | 167 | 0.070 |
Why?
| | RANK Ligand | 1 | 2008 | 29 | 0.070 |
Why?
| | Liver Neoplasms | 1 | 2015 | 787 | 0.070 |
Why?
| | Iohexol | 1 | 2008 | 23 | 0.070 |
Why?
| | Aorta, Abdominal | 1 | 2008 | 52 | 0.070 |
Why?
| | Radiographic Image Enhancement | 1 | 2008 | 57 | 0.070 |
Why?
| | Breeding | 2 | 2014 | 64 | 0.070 |
Why?
| | Blood Platelets | 1 | 2011 | 381 | 0.070 |
Why?
| | Androgens | 1 | 2009 | 181 | 0.070 |
Why?
| | Scleroderma, Systemic | 1 | 2008 | 123 | 0.070 |
Why?
| | Receptors, Glucocorticoid | 1 | 2009 | 132 | 0.070 |
Why?
| | Alanine Transaminase | 2 | 2019 | 151 | 0.060 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2007 | 57 | 0.060 |
Why?
| | Young Adult | 6 | 2024 | 14437 | 0.060 |
Why?
| | Adrenocorticotropic Hormone | 3 | 2017 | 147 | 0.060 |
Why?
| | Computer-Assisted Instruction | 1 | 2008 | 70 | 0.060 |
Why?
| | Observer Variation | 1 | 2008 | 358 | 0.060 |
Why?
| | Electronic Mail | 1 | 2007 | 63 | 0.060 |
Why?
| | Vagina | 2 | 2020 | 206 | 0.060 |
Why?
| | Mutation | 3 | 2017 | 4130 | 0.060 |
Why?
| | Hepatic Encephalopathy | 1 | 2007 | 25 | 0.060 |
Why?
| | Membrane Proteins | 1 | 1993 | 1171 | 0.060 |
Why?
| | Alcohol Dehydrogenase | 1 | 2006 | 21 | 0.060 |
Why?
| | Aortic Aneurysm, Abdominal | 1 | 2008 | 168 | 0.060 |
Why?
| | Adrenal Cortex | 1 | 2006 | 33 | 0.060 |
Why?
| | Ovarian Neoplasms | 1 | 2012 | 599 | 0.060 |
Why?
| | Superoxide Dismutase | 2 | 2019 | 308 | 0.060 |
Why?
| | Cytokine Receptor gp130 | 1 | 2006 | 11 | 0.060 |
Why?
| | Adolescent | 8 | 2020 | 22825 | 0.060 |
Why?
| | Cecum | 1 | 2026 | 37 | 0.060 |
Why?
| | False Positive Reactions | 1 | 2026 | 124 | 0.060 |
Why?
| | Computer Simulation | 2 | 2023 | 1018 | 0.060 |
Why?
| | Pentacyclic Triterpenes | 1 | 2026 | 12 | 0.060 |
Why?
| | Up-Regulation | 2 | 2019 | 848 | 0.060 |
Why?
| | Brain Chemistry | 2 | 2009 | 121 | 0.060 |
Why?
| | Prednisolone | 1 | 2006 | 67 | 0.060 |
Why?
| | Health Planning Guidelines | 1 | 2006 | 24 | 0.060 |
Why?
| | Receptors, Interleukin-6 | 1 | 2006 | 49 | 0.060 |
Why?
| | Solitary Nucleus | 1 | 2026 | 25 | 0.060 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2006 | 99 | 0.060 |
Why?
| | Culture | 1 | 2006 | 126 | 0.060 |
Why?
| | Self Administration | 1 | 2026 | 122 | 0.060 |
Why?
| | Australia | 1 | 2006 | 299 | 0.060 |
Why?
| | Bone Resorption | 1 | 2006 | 81 | 0.060 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2006 | 163 | 0.060 |
Why?
| | Heart Defects, Congenital | 1 | 2014 | 941 | 0.060 |
Why?
| | Program Evaluation | 2 | 2007 | 952 | 0.060 |
Why?
| | Vagus Nerve | 1 | 2026 | 92 | 0.060 |
Why?
| | Muscle Fatigue | 1 | 2006 | 98 | 0.060 |
Why?
| | Alleles | 2 | 2019 | 909 | 0.060 |
Why?
| | Germ-Free Life | 1 | 2025 | 33 | 0.050 |
Why?
| | Spheroids, Cellular | 1 | 2026 | 82 | 0.050 |
Why?
| | Phosphorylation | 2 | 2019 | 1721 | 0.050 |
Why?
| | Cells, Cultured | 3 | 2021 | 4169 | 0.050 |
Why?
| | Ultraviolet Rays | 1 | 2008 | 385 | 0.050 |
Why?
| | HIV Infections | 1 | 2020 | 3235 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2006 | 417 | 0.050 |
Why?
| | Predictive Value of Tests | 3 | 2020 | 2133 | 0.050 |
Why?
| | Rats, Sprague-Dawley | 2 | 2020 | 2542 | 0.050 |
Why?
| | Schools | 1 | 2008 | 453 | 0.050 |
Why?
| | Elective Surgical Procedures | 1 | 2006 | 203 | 0.050 |
Why?
| | Health Promotion | 2 | 2008 | 792 | 0.050 |
Why?
| | Pregnancy | 4 | 2022 | 7274 | 0.050 |
Why?
| | Acetylation | 1 | 2024 | 262 | 0.050 |
Why?
| | Sports | 1 | 2006 | 216 | 0.050 |
Why?
| | Molecular Sequence Annotation | 1 | 2024 | 109 | 0.050 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2008 | 794 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2679 | 0.050 |
Why?
| | Case-Control Studies | 4 | 2017 | 3660 | 0.050 |
Why?
| | Cystic Fibrosis | 1 | 1993 | 1171 | 0.050 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2006 | 187 | 0.050 |
Why?
| | Albumins | 1 | 2023 | 119 | 0.050 |
Why?
| | Actin Cytoskeleton | 1 | 2024 | 103 | 0.050 |
Why?
| | Survival Rate | 2 | 2019 | 2110 | 0.050 |
Why?
| | Environmental Exposure | 1 | 2008 | 583 | 0.050 |
Why?
| | Trastuzumab | 1 | 2023 | 119 | 0.050 |
Why?
| | Plant Extracts | 1 | 2025 | 191 | 0.050 |
Why?
| | Transforming Growth Factor beta | 1 | 2025 | 475 | 0.050 |
Why?
| | Leptin | 1 | 2004 | 249 | 0.050 |
Why?
| | Risk Assessment | 1 | 2012 | 3784 | 0.050 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2025 | 512 | 0.050 |
Why?
| | Flow Cytometry | 1 | 2026 | 1172 | 0.050 |
Why?
| | Microarray Analysis | 2 | 2015 | 117 | 0.050 |
Why?
| | Prospective Studies | 4 | 2020 | 8164 | 0.040 |
Why?
| | Prostatic Neoplasms | 1 | 2009 | 986 | 0.040 |
Why?
| | Health Behavior | 1 | 2007 | 799 | 0.040 |
Why?
| | Epigenomics | 1 | 2022 | 125 | 0.040 |
Why?
| | Patient Compliance | 1 | 2006 | 591 | 0.040 |
Why?
| | Actins | 1 | 2024 | 428 | 0.040 |
Why?
| | Odds Ratio | 2 | 2020 | 1084 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2011 | 849 | 0.040 |
Why?
| | Amino Acid Sequence | 2 | 2020 | 2134 | 0.040 |
Why?
| | Blotting, Western | 2 | 2015 | 1186 | 0.040 |
Why?
| | Mass Screening | 2 | 2010 | 1375 | 0.040 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2008 | 1431 | 0.040 |
Why?
| | Rats, Inbred Lew | 1 | 2001 | 105 | 0.040 |
Why?
| | Iodine | 1 | 2021 | 27 | 0.040 |
Why?
| | Photoreceptor Cells, Invertebrate | 1 | 2020 | 4 | 0.040 |
Why?
| | Indians, North American | 1 | 2006 | 567 | 0.040 |
Why?
| | Pharmacogenomic Testing | 1 | 2021 | 63 | 0.040 |
Why?
| | Killer Cells, Natural | 1 | 2004 | 481 | 0.040 |
Why?
| | DNA, Complementary | 1 | 2001 | 273 | 0.040 |
Why?
| | Rats, Inbred F344 | 1 | 2001 | 269 | 0.040 |
Why?
| | Curriculum | 1 | 2008 | 1082 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2017 | 11947 | 0.040 |
Why?
| | Time Factors | 4 | 2019 | 7173 | 0.040 |
Why?
| | Multiple Sclerosis | 1 | 2006 | 491 | 0.040 |
Why?
| | Oxysterols | 1 | 2020 | 2 | 0.040 |
Why?
| | Cannabinoid Receptor Agonists | 1 | 2020 | 44 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2022 | 230 | 0.040 |
Why?
| | Magnetic Resonance Angiography | 1 | 2022 | 251 | 0.040 |
Why?
| | Cytomegalovirus | 1 | 2021 | 172 | 0.040 |
Why?
| | Carbon | 1 | 2021 | 176 | 0.040 |
Why?
| | Kainic Acid | 1 | 2020 | 33 | 0.040 |
Why?
| | Monte Carlo Method | 1 | 2020 | 148 | 0.040 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2020 | 75 | 0.040 |
Why?
| | DNA Primers | 1 | 2001 | 505 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2006 | 1776 | 0.040 |
Why?
| | Catheterization | 1 | 2000 | 184 | 0.040 |
Why?
| | Aspartate Aminotransferases | 1 | 2019 | 86 | 0.040 |
Why?
| | Protective Agents | 1 | 2019 | 43 | 0.040 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 69 | 0.040 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2019 | 153 | 0.040 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2019 | 88 | 0.040 |
Why?
| | Heme Oxygenase-1 | 1 | 2019 | 76 | 0.040 |
Why?
| | Urinary Bladder Diseases | 1 | 2019 | 18 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2022 | 6543 | 0.040 |
Why?
| | Lipid Peroxidation | 1 | 2019 | 169 | 0.040 |
Why?
| | Metabolic Syndrome | 2 | 2017 | 365 | 0.040 |
Why?
| | Benchmarking | 1 | 2020 | 194 | 0.040 |
Why?
| | Transplant Recipients | 1 | 2021 | 183 | 0.040 |
Why?
| | Hedgehog Proteins | 1 | 2020 | 201 | 0.040 |
Why?
| | Emtricitabine | 1 | 2020 | 210 | 0.040 |
Why?
| | Sample Size | 1 | 2019 | 124 | 0.040 |
Why?
| | Group IV Phospholipases A2 | 1 | 2019 | 46 | 0.040 |
Why?
| | Biological Transport | 1 | 2020 | 425 | 0.040 |
Why?
| | Bacteria | 1 | 2025 | 769 | 0.040 |
Why?
| | Sensation | 1 | 1999 | 55 | 0.040 |
Why?
| | Cerebellum | 1 | 2001 | 227 | 0.040 |
Why?
| | Education | 1 | 2019 | 106 | 0.040 |
Why?
| | Muscle, Skeletal | 2 | 2006 | 1798 | 0.040 |
Why?
| | Caspase 3 | 1 | 2019 | 242 | 0.040 |
Why?
| | Molecular Weight | 1 | 2019 | 313 | 0.040 |
Why?
| | Birth Weight | 1 | 2022 | 522 | 0.040 |
Why?
| | Substance Abuse Detection | 1 | 2020 | 112 | 0.040 |
Why?
| | Colitis, Ulcerative | 1 | 2000 | 149 | 0.040 |
Why?
| | Normal Distribution | 1 | 2018 | 22 | 0.040 |
Why?
| | Lysosomes | 1 | 2019 | 133 | 0.040 |
Why?
| | Pulmonary Circulation | 1 | 2021 | 434 | 0.040 |
Why?
| | Urogenital Abnormalities | 1 | 2019 | 71 | 0.040 |
Why?
| | Ligaments | 1 | 2019 | 76 | 0.040 |
Why?
| | Protons | 1 | 2019 | 96 | 0.030 |
Why?
| | Absorptiometry, Photon | 2 | 2012 | 277 | 0.030 |
Why?
| | Rats, Transgenic | 1 | 2018 | 20 | 0.030 |
Why?
| | Sirtuins | 1 | 2019 | 50 | 0.030 |
Why?
| | Metyrapone | 1 | 2018 | 5 | 0.030 |
Why?
| | Receptors, AMPA | 1 | 2020 | 147 | 0.030 |
Why?
| | GABA-A Receptor Antagonists | 1 | 2018 | 19 | 0.030 |
Why?
| | Neuroimaging | 1 | 2021 | 309 | 0.030 |
Why?
| | Computer Graphics | 1 | 2018 | 41 | 0.030 |
Why?
| | Colorado | 3 | 2020 | 4591 | 0.030 |
Why?
| | Dinitrobenzenes | 1 | 2018 | 5 | 0.030 |
Why?
| | Age of Onset | 1 | 2020 | 568 | 0.030 |
Why?
| | Fluorescent Dyes | 1 | 2020 | 342 | 0.030 |
Why?
| | Mice, 129 Strain | 1 | 2018 | 85 | 0.030 |
Why?
| | Analgesics | 1 | 2020 | 231 | 0.030 |
Why?
| | Sirtuin 3 | 1 | 2019 | 60 | 0.030 |
Why?
| | Receptors, IgE | 1 | 2018 | 43 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2019 | 264 | 0.030 |
Why?
| | Cardiovascular Diseases | 2 | 2008 | 2218 | 0.030 |
Why?
| | Metabolic Networks and Pathways | 1 | 2019 | 175 | 0.030 |
Why?
| | Rectum | 1 | 2019 | 183 | 0.030 |
Why?
| | Uterus | 1 | 2019 | 228 | 0.030 |
Why?
| | Ribosomes | 1 | 2019 | 193 | 0.030 |
Why?
| | Abdominal Pain | 1 | 1999 | 149 | 0.030 |
Why?
| | Magnetite Nanoparticles | 1 | 2017 | 27 | 0.030 |
Why?
| | Thioredoxins | 1 | 2017 | 30 | 0.030 |
Why?
| | Azo Compounds | 1 | 2017 | 30 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2019 | 762 | 0.030 |
Why?
| | Organ Specificity | 1 | 2018 | 310 | 0.030 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2017 | 76 | 0.030 |
Why?
| | Crigler-Najjar Syndrome | 1 | 1997 | 2 | 0.030 |
Why?
| | Protein Structure, Secondary | 1 | 2018 | 372 | 0.030 |
Why?
| | Metal Nanoparticles | 1 | 2018 | 80 | 0.030 |
Why?
| | Heterozygote | 3 | 1994 | 317 | 0.030 |
Why?
| | Dronabinol | 1 | 2020 | 251 | 0.030 |
Why?
| | Glucuronosyltransferase | 1 | 1997 | 18 | 0.030 |
Why?
| | Tuberculosis | 1 | 2020 | 289 | 0.030 |
Why?
| | Solubility | 2 | 2008 | 240 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2024 | 1339 | 0.030 |
Why?
| | DNA Damage | 1 | 2019 | 440 | 0.030 |
Why?
| | Cell Survival | 1 | 2020 | 1111 | 0.030 |
Why?
| | Drug Delivery Systems | 1 | 2020 | 381 | 0.030 |
Why?
| | Surface Properties | 1 | 2017 | 386 | 0.030 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2017 | 178 | 0.030 |
Why?
| | Medication Adherence | 1 | 2020 | 540 | 0.030 |
Why?
| | Exons | 2 | 1997 | 365 | 0.030 |
Why?
| | Genetic Linkage | 2 | 2007 | 273 | 0.030 |
Why?
| | Metabolome | 1 | 2019 | 391 | 0.030 |
Why?
| | Genotyping Techniques | 1 | 2016 | 72 | 0.030 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2018 | 233 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2021 | 1043 | 0.030 |
Why?
| | Lipogenesis | 1 | 2016 | 62 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2021 | 717 | 0.030 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2016 | 97 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2019 | 536 | 0.030 |
Why?
| | Autophagy | 1 | 2018 | 291 | 0.030 |
Why?
| | Iopamidol | 1 | 2015 | 12 | 0.030 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2018 | 199 | 0.030 |
Why?
| | Animals, Inbred Strains | 1 | 2015 | 6 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2008 | 3022 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2019 | 765 | 0.030 |
Why?
| | Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2015 | 19 | 0.030 |
Why?
| | Child | 4 | 2014 | 22979 | 0.030 |
Why?
| | Lipids | 1 | 2020 | 723 | 0.030 |
Why?
| | Codon | 2 | 1992 | 92 | 0.030 |
Why?
| | Length of Stay | 1 | 2021 | 1371 | 0.030 |
Why?
| | Heart | 1 | 2018 | 628 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 852 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2019 | 901 | 0.030 |
Why?
| | Genetic Testing | 1 | 1997 | 493 | 0.030 |
Why?
| | Principal Component Analysis | 1 | 2015 | 196 | 0.030 |
Why?
| | Glutathione | 1 | 2016 | 370 | 0.030 |
Why?
| | Histones | 1 | 2019 | 672 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2015 | 398 | 0.030 |
Why?
| | Gene Deletion | 1 | 2015 | 392 | 0.030 |
Why?
| | Gene Frequency | 1 | 2015 | 498 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2016 | 440 | 0.020 |
Why?
| | Saliva | 2 | 2006 | 252 | 0.020 |
Why?
| | Prevalence | 1 | 2021 | 2889 | 0.020 |
Why?
| | Triglycerides | 1 | 2016 | 529 | 0.020 |
Why?
| | Radiation Dosage | 1 | 2015 | 194 | 0.020 |
Why?
| | Chelation Therapy | 1 | 2013 | 10 | 0.020 |
Why?
| | Iron Chelating Agents | 1 | 2013 | 17 | 0.020 |
Why?
| | Cell Line | 1 | 2019 | 2832 | 0.020 |
Why?
| | Chronic Disease | 1 | 2019 | 1844 | 0.020 |
Why?
| | Carrier Proteins | 1 | 2017 | 731 | 0.020 |
Why?
| | Mice, Transgenic | 2 | 2010 | 2197 | 0.020 |
Why?
| | Ovarian Diseases | 1 | 2012 | 14 | 0.020 |
Why?
| | Entropy | 1 | 2012 | 44 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2020 | 2054 | 0.020 |
Why?
| | Protein Binding | 1 | 2019 | 2249 | 0.020 |
Why?
| | Databases, Factual | 1 | 2018 | 1504 | 0.020 |
Why?
| | Thalassemia | 1 | 1992 | 6 | 0.020 |
Why?
| | Glucose | 1 | 2017 | 1051 | 0.020 |
Why?
| | Exome | 1 | 2013 | 233 | 0.020 |
Why?
| | Ultrasonography, Doppler | 1 | 2012 | 126 | 0.020 |
Why?
| | Data Mining | 1 | 2012 | 114 | 0.020 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 6164 | 0.020 |
Why?
| | Blood Cell Count | 1 | 2011 | 55 | 0.020 |
Why?
| | Transferrin | 1 | 2011 | 50 | 0.020 |
Why?
| | DNA | 3 | 1994 | 1444 | 0.020 |
Why?
| | Models, Biological | 1 | 2019 | 1772 | 0.020 |
Why?
| | Liver Function Tests | 1 | 2011 | 105 | 0.020 |
Why?
| | Reference Standards | 1 | 2011 | 177 | 0.020 |
Why?
| | Genetics, Behavioral | 1 | 2010 | 17 | 0.020 |
Why?
| | Placenta | 1 | 2018 | 793 | 0.020 |
Why?
| | Thermosensing | 1 | 2010 | 12 | 0.020 |
Why?
| | Haplotypes | 1 | 2012 | 509 | 0.020 |
Why?
| | Ovary | 1 | 2012 | 236 | 0.020 |
Why?
| | Software Design | 1 | 2010 | 25 | 0.020 |
Why?
| | Clinical Competence | 1 | 2019 | 1260 | 0.020 |
Why?
| | Crosses, Genetic | 1 | 2010 | 123 | 0.020 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 1 | 2011 | 232 | 0.020 |
Why?
| | Obesity | 1 | 2004 | 3149 | 0.020 |
Why?
| | Neurons | 1 | 2020 | 1672 | 0.020 |
Why?
| | Antisocial Personality Disorder | 1 | 2011 | 123 | 0.020 |
Why?
| | Contraindications | 1 | 2010 | 90 | 0.020 |
Why?
| | Asymptomatic Diseases | 1 | 2010 | 104 | 0.020 |
Why?
| | Immunoblotting | 1 | 2010 | 296 | 0.020 |
Why?
| | Blood Proteins | 1 | 2011 | 239 | 0.020 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 1993 | 374 | 0.020 |
Why?
| | 11-beta-Hydroxysteroid Dehydrogenase Type 1 | 1 | 2009 | 10 | 0.020 |
Why?
| | 11-beta-Hydroxysteroid Dehydrogenase Type 2 | 1 | 2009 | 10 | 0.020 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2010 | 99 | 0.020 |
Why?
| | Corticosterone | 1 | 2010 | 241 | 0.020 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 2008 | 42 | 0.020 |
Why?
| | Sex Factors | 1 | 2015 | 2136 | 0.020 |
Why?
| | Mice, Inbred CBA | 1 | 2008 | 57 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2012 | 1518 | 0.020 |
Why?
| | Social Marketing | 1 | 2008 | 15 | 0.020 |
Why?
| | New Mexico | 1 | 2008 | 105 | 0.020 |
Why?
| | Mice, Inbred C3H | 1 | 2008 | 254 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 980 | 0.020 |
Why?
| | Rural Health | 1 | 2008 | 87 | 0.020 |
Why?
| | Meta-Analysis as Topic | 1 | 2008 | 173 | 0.020 |
Why?
| | Brain Mapping | 1 | 2010 | 550 | 0.020 |
Why?
| | Pituitary Function Tests | 1 | 2007 | 2 | 0.020 |
Why?
| | Receptor Activator of Nuclear Factor-kappa B | 1 | 2007 | 9 | 0.020 |
Why?
| | Fruit | 1 | 2008 | 146 | 0.020 |
Why?
| | Sunlight | 1 | 2008 | 79 | 0.020 |
Why?
| | Vegetables | 1 | 2008 | 162 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2009 | 394 | 0.020 |
Why?
| | Aldehyde Dehydrogenase, Mitochondrial | 1 | 2006 | 23 | 0.020 |
Why?
| | Myoglobin | 1 | 2006 | 13 | 0.020 |
Why?
| | Stochastic Processes | 1 | 2007 | 65 | 0.020 |
Why?
| | Acetaldehyde | 1 | 2006 | 17 | 0.020 |
Why?
| | Retinal Dehydrogenase | 1 | 2006 | 29 | 0.020 |
Why?
| | Adrenal Glands | 1 | 2007 | 77 | 0.020 |
Why?
| | Genetic Carrier Screening | 2 | 1997 | 32 | 0.020 |
Why?
| | Pituitary Gland | 1 | 2007 | 149 | 0.010 |
Why?
| | Electrophysiology | 1 | 2006 | 219 | 0.010 |
Why?
| | Osteoclasts | 1 | 2006 | 57 | 0.010 |
Why?
| | Reminder Systems | 1 | 2007 | 147 | 0.010 |
Why?
| | Injections, Intravenous | 1 | 2006 | 198 | 0.010 |
Why?
| | Hip Prosthesis | 1 | 2006 | 42 | 0.010 |
Why?
| | Hormones | 1 | 2006 | 136 | 0.010 |
Why?
| | Bone and Bones | 1 | 2008 | 322 | 0.010 |
Why?
| | Educational Status | 1 | 2008 | 475 | 0.010 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2006 | 269 | 0.010 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2006 | 212 | 0.010 |
Why?
| | Lactic Acid | 1 | 2006 | 295 | 0.010 |
Why?
| | Physical Endurance | 1 | 2006 | 279 | 0.010 |
Why?
| | Pedigree | 2 | 1997 | 522 | 0.010 |
Why?
| | Educational Measurement | 1 | 2008 | 332 | 0.010 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2004 | 61 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2004 | 330 | 0.010 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2004 | 91 | 0.010 |
Why?
| | Electromyography | 1 | 2006 | 419 | 0.010 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2004 | 224 | 0.010 |
Why?
| | Anthropometry | 1 | 2004 | 206 | 0.010 |
Why?
| | Dietary Carbohydrates | 1 | 2004 | 147 | 0.010 |
Why?
| | Interleukin-2 | 1 | 2004 | 440 | 0.010 |
Why?
| | Biomechanical Phenomena | 1 | 2006 | 873 | 0.010 |
Why?
| | Vitamin D | 1 | 2006 | 405 | 0.010 |
Why?
| | Dietary Fats | 1 | 2004 | 309 | 0.010 |
Why?
| | Cohort Studies | 1 | 2012 | 6099 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2004 | 1492 | 0.010 |
Why?
| | Skin Neoplasms | 1 | 2008 | 865 | 0.010 |
Why?
| | Patient Selection | 1 | 2004 | 746 | 0.010 |
Why?
| | Viscera | 1 | 1999 | 17 | 0.010 |
Why?
| | Patient Acceptance of Health Care | 1 | 2006 | 895 | 0.010 |
Why?
| | Psychological Tests | 1 | 1999 | 131 | 0.010 |
Why?
| | Research Design | 1 | 2004 | 1157 | 0.010 |
Why?
| | Age Factors | 1 | 2006 | 3372 | 0.010 |
Why?
| | Cytokines | 1 | 2006 | 2086 | 0.010 |
Why?
| | Pain Measurement | 1 | 2000 | 569 | 0.010 |
Why?
| | Child, Preschool | 2 | 2008 | 12016 | 0.010 |
Why?
| | Perception | 1 | 2000 | 378 | 0.010 |
Why?
| | Genetics, Population | 1 | 1997 | 226 | 0.010 |
Why?
| | Prenatal Diagnosis | 1 | 1997 | 196 | 0.010 |
Why?
| | Registries | 1 | 2004 | 2434 | 0.010 |
Why?
| | Body Mass Index | 1 | 2004 | 2470 | 0.010 |
Why?
| | Homozygote | 1 | 1994 | 199 | 0.010 |
Why?
| | Frameshift Mutation | 1 | 1992 | 32 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 332 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 1992 | 1046 | 0.000 |
Why?
| | Infant | 1 | 1997 | 10194 | 0.000 |
Why?
|
|
Saba's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|